{"id":4436,"date":"2026-10-12T08:33:23","date_gmt":"2026-10-12T08:33:23","guid":{"rendered":"https:\/\/nhdbio.com\/?p=4436"},"modified":"2026-10-12T08:33:23","modified_gmt":"2026-10-12T08:33:23","slug":"protocole-de-lessai-triumph-de-lexercice-avec-le-tesamorelin","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/tesamorelin-exercise-triumph-trial-protocol\/","title":{"rendered":"T\u00e9samor\u00e9line plus exercice : comprendre le protocole de l'essai TRIUMPH chez les adultes plus \u00e2g\u00e9s vivant avec le VIH"},"content":{"rendered":"
\n
\"Thematic
Editorial illustration, not an experimental photograph.<\/figcaption><\/figure>\n

What was published here is a trial protocol. It describes how a study is being planned, not an effect that has already been proven. It combines tesamorelin with home exercise and focuses on physical function in older adults living with HIV.<\/p>\n

\n

Why can't we look only at belly fat?<\/h2>\n

For some older adults, walking, standing up, and completing daily activities matter more directly than a number on the scale. Belly fat, muscle mass, and physical function are related, but they cannot substitute for one another.<\/p>\n

The study therefore treats functional performance as an important question: after body composition changes, are people actually able to move more easily? This needs to be measured directly, not inferred only from imaging or body weight.<\/p>\n<\/section>\n

\n

Who is planned to be included?<\/h2>\n

The TRIUMPH protocol plans to enroll 100 adults living with HIV aged 50 to 80 at two centers. They are relatively inactive, have frailty or are at risk of frailty, and have a higher amount of belly fat.[1]<\/a><\/p>\n

This population is very specific. Even if future results are positive, they cannot be transferred without conditions to younger healthy people or to all older adults. It is also not the same study as the TRIUMPH series in retatrutide development that shares the same name.<\/p>\n<\/section>\n

\n

Both groups exercise, so the difference from adding the drug can be seen<\/h2>\n

Participants are randomly assigned to receive tesamorelin or placebo, and both groups do home-based semi-supervised exercise for 24 weeks, followed by a 24-week extension phase of independent exercise.[1]<\/a><\/p>\n

This design is meant to compare \u201cexercise plus drug\u201d with \u201cexercise plus placebo.\u201d It does not compare an exercise group with people who do no exercise at all, so future results should be understood in light of this control.<\/p>\n